HEPATITIS VACCINE MARKET ANALYSIS

Hepatitis is an infectious disease caused due to hepatitis virus type A, B, and C, which leads to liver associated disease such as Hepatitis A, hepatitis B, hepatitis C,  liver cirrhosis, hepatocellular carcinoma, and liver failure. It may lead to death of infected person. The infection is spread due to transmission of hepatitis A and hepatitis B virus due contact with body fluids (blood etc.) of infected person. Hepatitis vaccine are available for prevention of both hepatitis A and hepatitis B which prevents its occurrence by boosting immunity of the person thereby avoiding complications such as liver failure and cancer. Infection is most prevalent in children. Globally hepatitis B is more prevalent than hepatitis A.

Market Dynamics

Hepatitis is one of the most prevalent infectious disease across the globe, it attracted attention from health bodies such as World Health Organization (WHO) due to its severity. Increasing incidence of hepatitis worldwide is estimated to drive growth of the hepatitis vaccine market.  According to World Hepatitis Report published in 2017 by WHO, an estimated 325 million people worldwide are living with chronic hepatitis B virus infection (HBV) or hepatitis C virus (HCV) infection. Moreover, an estimated 1.34 million deaths in 2015, were caused due to viral hepatitis. Around 1.75 million people were infected with hepatitis B virus infection (HCV) in 2015. Increasing global population (live births) is another factor driving growth of the hepatitis vaccine market. As per statistics given by the World Population Report published in 2017, world population would surpass mark of 9 billion by 2025 thereby adding more live birth each year. According to guideline published by WHO, vaccine for hepatitis B has to administer within first 24 hour of the birth in order to prevent the hepatitis B infection to infant. Furthermore, increased awareness amongst masses about benefits of hepatitis vaccination would further aid in market growth for the hepatitis vaccine market. Various companies are introducing the vaccine product to prevent hepatitis A and hepatitis B which would lead to higher competition and expansion of the global hepatitis vaccine market. For instance, in September 2017, Dynavax Technologies Corporation received the U.S. Food and Drug Administration (FDA) has approval for its hepatitis B vaccine HEPLISAV-B to be used in adults 18 years and older.

However cost associated with these vaccines in both Hepatitis A and Hepatitis B is matter of concern. Government support is essential for the common affordability of hepatitis vaccine, even though WHO and many national government took initiative to better target hepatitis vaccine. Accessibility of these vaccines is still low especially in remote locations in emerging markets such as Asia Pacific and Africa where increased incidence is observed, which may limit the growth of market. There is attractive opportunity to introduce hepatitis C vaccine as it is one of most prevalent type of hepatitis after hepatitis B and has no vaccine available for it. Also, currently available vaccine for hepatitis B are ineffective in many adults along with those suffering from diabetes. In these cases person do not develop adequate immunity even after two or three shots of vaccine. Therefore, new improved vaccine could prove beneficial and propel growth of the market.  

Regional Dynamics

On the basis of regions, hepatitis vaccine market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to dominate the hepatitis vaccine market, owing to high healthcare spending and availability of robust healthcare infrastructure in the region. According to Centre for Disease Control (CDC) data in 2016, the U.S. had 0.6 cases per 1, 00,000 population. Even though this rate of incidence is low as compared to regions such as Asia Pacific and Africa, still due to highest healthcare spending by U.S. population hepatitis vaccine North America is lucrative market for hepatitis vaccine market. Asia Pacific has greatest burden of hepatitis (154 million people with hepatitis B) currently as mentioned in World Hepatitis Report, 2017 and it is attractive market for hepatitis market due to the larger population getting infected from the hepatitis. According to the WHO, it is estimated that 2% to 5% of general population is affected chronically in Asia Pacific. Prevalence of hepatitis B is the highest in Middle East & Africa where adult population is chronically infected.

Competitive Analysis

Key players present in the hepatitis vaccines market are Merck and Company, GlaxoSmithKline, Sanofi Pasture, CSL Behring GmbH, Novartis AG and Pfizer Inc. Few leading brands in hepatitis vaccine market are Engerix-B, Havrix (Glaxosmithkline), Recombivax, Vaqta (Merck and Company), Euvax – Avaxim (Sanofi Pasteur), and Shanvac B (Shantha Biotech)

Market Taxonomy 

On the basis of Indication

• Hepatitis A
• Hepatitis B

On the basis of Vaccine Type

• Recombinant Vaccine
• Inactivated Vaccine

On the basis of Distribution Channel

• Hospitals
• Retail Pharmacy
• Online Pharmacy

Amongst indication, hepatitis B vaccine holds larger market share due to higher prevalence of hepatitis B infection and presence of different companies in the production and marketing of these vaccine. Recombinant vaccine is largest shareholder in vaccine type segment as it is most commonly used in the hepatitis B vaccine. Amongst distribution channel retail pharmacy holds major share.